Joinn Laboratories(China)Co.,Ltd.
Joinn Laboratories(China)Co.,Ltd. Fundamental Analysis
Joinn Laboratories(China)Co.,Ltd. (6127.HK) shows weak financial fundamentals with a PE ratio of 46.57, profit margin of 17.97%, and ROE of 3.65%. The company generates $3.0B in annual revenue with weak year-over-year growth of -15.07%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 32.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 6127.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak6127.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate6127.HK shows balanced valuation metrics.
Growth Score
Weak6127.HK faces weak or negative growth trends.
Financial Health Score
Excellent6127.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate6127.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 6127.HK Expensive or Cheap?
P/E Ratio
6127.HK trades at 46.57 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 6127.HK's PEG of 1.54 indicates fair valuation.
Price to Book
The market values Joinn Laboratories(China)Co.,Ltd. at 1.67 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 106.25 times EBITDA. This signals the market has high growth expectations.
How Well Does 6127.HK Make Money?
Net Profit Margin
For every $100 in sales, Joinn Laboratories(China)Co.,Ltd. keeps $17.97 as profit after all expenses.
Operating Margin
Core operations generate 14.95 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.65 in profit for every $100 of shareholder equity.
ROA
Joinn Laboratories(China)Co.,Ltd. generates $3.08 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Joinn Laboratories(China)Co.,Ltd. generates strong operating cash flow of $897.90M, reflecting robust business health.
Free Cash Flow
Joinn Laboratories(China)Co.,Ltd. generates strong free cash flow of $631.83M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.46 in free cash annually.
FCF Yield
6127.HK converts 1.35% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
46.57
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.54
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.67
vs 25 benchmark
P/S Ratio
Price to sales ratio
15.39
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.53
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How 6127.HK Stacks Against Its Sector Peers
| Metric | 6127.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 46.57 | 28.45 | Worse (Expensive) |
| ROE | 3.65% | 763.00% | Weak |
| Net Margin | 17.97% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 4.53 | 2795.60 | Strong Liquidity |
| ROA | 3.08% | -16588.00% (disorted) | Weak |
6127.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Joinn Laboratories(China)Co.,Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
163.13%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-65.38%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
90.77%
Industry Style: Defensive, Growth, Innovation
High Growth